Regulation and Prequalification
Progress towards enhancing regulatory practices related to medical products around the world is supported by capacity building, promoting regulatory convergence and harmonization.

Regulatory updates on Zika virus disease

Zika virus disease (IVDs) emergency use assessment and listing (EUAL) status after PHEIC termination

On 18 November 2016, the Director-General declared the end of the Public Health Emergency of International Concern (PHEIC) for Zika virus infection and to transition to a longer-term response mechanism. The WHO Prequalification Team will no longer be assessing new applications under the Emergency Use Assessment and Listing Procedure (EUAL) procedure for Zika virus IVDs.

Public Reports: WHO list of IVDs for Zika virus disease accepted for procurement through the EUAL Procedure for IVDs.

Consultation on the EUAL for ZIKV IVDs

Consultation on the EUAL for ZIKV IVDs

A consultation with experts was held in Geneva on 14 and 15 March 2016. The purpose of the consultation was to identify and formalize the minimal technical requirements required for the documentary evidence and to invite expert review of the WHO protocols for the performance evaluations. Additionally, the consultation provided advice to WHO on how to best leverage available evidence of product safety and performance through an abbreviated EUAL assessment.